India, May 18 -- HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company, on Thursday announced its first quarter financial results, and provided various business updates.
Shares rose by over 25% on Monday.
Q1 2026:
Allarity recorded a net income of $3.5 million, or $0.17 per share in the first quarter, while in the same period of 2025 it reported a net loss of $2.2 million, or $0.25 per share.
Revenues reached $6.5 million, a significant rise from the $5,065 from a year ago. The company earned a sizeable amount of revenue from various licensing deals, including a deal with Wugen and with Trimmune for the licensing of HCW11-006.
Research and development expenses (R&D) were $1.3 million, 15% lesser than the $1.5 million re...